Efficacy and safety of continuing for a total of 48 [standard treatment] or prolonging for a total of 72 [prolonged treatment] weeks of combined treatment of patients receiving Pegasys [peginterferon alfa-2a] and Copegus [ribavirin] who are biochemical responders but virological non-responders at week 12 or week 24.

Trial Profile

Efficacy and safety of continuing for a total of 48 [standard treatment] or prolonging for a total of 72 [prolonged treatment] weeks of combined treatment of patients receiving Pegasys [peginterferon alfa-2a] and Copegus [ribavirin] who are biochemical responders but virological non-responders at week 12 or week 24.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms ProPeg
  • Most Recent Events

    • 14 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top